Geron Corporation
(NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation ...

Website: http://www.geron.com

Founded: 1990

Full Time Employees: 45

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2005-09-30	2005-06-30	2005-03-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-09-30	2002-06-30	2002-03-31

revenues:
product revenue	51,771,000	48,013,000	47,167,000	49,007,000	39,436,000	47,506,000	28,209,000	780,000
royalties	66,000	2,000	60,000	29,000	167,000	117,000	62,000	102,000	304,000	53,500	164,000	29,000	21,000				123,000
total revenues	51,837,000	33,966,500	47,227,000	49,036,000	39,603,000	7,364,250	28,271,000	882,000																														5,108,000			35,363,000									636,000	130,000	1,254,000	251,000	220,000	462,000	1,505,000	1,098,000	546,000	1,001,000	918,000	605,000	494,000	183,000	444,000	544,000	367,000	198,000	4,687,000	1,130,000	889,000	916,000	4,066,000	723,000	786,000	673,000	4,671,000		101,000		248,000
yoy	30.89%	361.24%	67.05%	5459.64%																																														189.09%	-71.86%	-16.68%	-77.14%	-59.71%	-53.85%	63.94%	81.49%	10.53%	446.99%	106.76%	11.21%	34.60%	-7.58%	-90.53%	-51.86%	-58.72%	-78.38%	15.27%	56.29%	13.10%	36.11%	-12.95%		678.22%		1783.47%
qoq	52.61%	-28.08%	-3.69%	23.82%	437.77%	-73.95%	3105.33%																																											389.23%	-89.63%	399.60%	14.09%	-52.38%	-69.30%	37.07%	101.10%	-45.45%	9.04%	51.74%	22.47%	169.95%	-58.78%	-18.38%	48.23%	85.35%	-95.78%	314.78%	27.11%	-2.95%	-77.47%	462.38%	-8.02%	16.79%	-85.59%
costs and operating expenses:
cost of goods sold	1,692,000	1,306,000	1,043,000	1,190,000	1,206,000	783,000	456,000	17,000
research and development	14,956,000	13,549,000	21,070,000	21,736,000	15,078,000	23,433,000	20,153,000	30,779,000	29,373,000	32,911,000	29,426,000	35,490,000	27,219,000	28,210,000	24,603,000	20,606,000	22,099,000	24,150,000	18,527,000	21,937,000	21,113,000	16,228,000	13,613,000	10,845,000	10,802,000	24,923,000	11,109,000	10,134,000	5,906,000	5,081,000	2,707,000	3,204,000	2,440,000	2,523,000	2,637,000	2,499,000	3,374,000	4,319,000	4,575,000	5,033,000	4,050,000	4,812,000	4,987,000	5,994,000	5,151,000	5,211,000	5,338,000	4,807,000	7,999,000	11,684,000	12,777,000	15,107,000															11,614,000	15,011,000	12,326,000	14,098,000	13,189,000	5,688,000	10,703,000	9,326,000	12,183,000	6,824,000	6,473,000	8,900,000		5,718,000	4,900,000	4,864,000	7,772,000	6,964,000	6,346,000	8,146,000	10,164,000
selling, general and administrative	35,425,000	41,668,000	39,001,000	38,564,000	40,023,000	43,371,000	35,877,000	39,419,000
restructuring charges	-394,000																																									941,000	406,000				116,000	838,000
total costs and operating expenses	51,679,000	73,555,000	61,114,000
income from operations	158,000	-25,540,000	-13,887,000	-12,454,000	-16,704,000	-20,050,000	-28,215,000	-69,333,000	-56,134,000	-54,289,000	-47,612,000	-51,951,000	-40,092,000	-41,951,000	-39,948,000	-27,976,000	-28,675,000	-30,982,000	-25,674,000	-28,889,000	-28,454,000	-23,266,000	-20,015,000	-16,762,000	-16,870,000	-30,008,000	-15,972,000	-15,224,000	-11,301,000	-9,589,000	-6,805,000	-7,242,000	-7,437,000	-7,786,000	-7,244,000						27,020,000											-18,918,000	-30,408,000	-19,936,000	-21,416,000	-24,356,000	-59,611,000	-18,203,000	-16,876,000	-16,477,000	-18,372,000	-16,400,000	-18,757,000	-16,705,000	-17,703,000	-17,934,000	-15,458,000	-14,336,000	-15,335,000	-16,766,000	-16,402,000	-3,346,000	-12,094,000	-11,408,000	-12,921,000	-3,897,000	-10,363,000	-10,475,000		-52,011,000	-5,483,500	-5,237,000	-8,653,000	-8,044,000	-7,442,000	-9,488,000	-11,134,000
yoy	-100.95%	27.38%	-50.78%	-82.04%	-70.24%	-63.07%	-40.74%	33.46%	40.01%	29.41%	19.18%	85.70%	39.82%	35.40%	55.60%	-3.16%	0.78%	33.16%	28.27%	72.35%	68.67%	-22.47%	25.31%	10.10%	49.28%	212.94%	134.71%	110.22%	51.96%	23.16%	-6.06%																					-22.33%	-48.99%	9.52%	26.90%	47.82%	224.47%	10.99%	-10.03%	-1.36%	3.78%	-8.55%	21.34%	16.52%	15.44%	6.97%	-5.76%	328.45%	26.80%	46.97%	26.94%	-14.14%	16.70%	8.91%		-92.51%	88.99%	100.02%		546.58%	-26.32%	-44.80%	-22.28%
qoq	-100.62%	83.91%	11.51%	-25.44%	-16.69%	-28.94%	-59.31%	23.51%	3.40%	14.02%	-8.35%	29.58%	-4.43%	5.01%	42.79%	-2.44%	-7.45%	20.67%	-11.13%	1.53%	22.30%	16.24%	19.41%	-0.64%	-43.78%	87.88%	4.91%	34.71%	17.85%	40.91%	-6.03%	-2.62%	-4.48%	7.48%																		-37.79%	52.53%	-6.91%	-12.07%	-59.14%	227.48%	7.86%	2.42%	-10.31%	12.02%	-12.57%	12.28%	-5.64%	-1.29%	16.02%	7.83%	-6.51%	-8.54%	2.22%	390.20%	-72.33%	6.01%	-11.71%	231.56%	-62.40%	-1.07%			848.50%	4.71%	-39.48%	7.57%	8.09%	-21.56%	-14.78%
operating margin %	0.30%	-75.19%	-29.40%	-25.40%	-42.18%	-272.26%	-99.80%	-7860.88%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	NaN%	0%	NaN%	NaN%	76.41%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	0%	0%	-1508.61%	-12114.74%	-9061.82%	-4635.50%	-1618.34%	-5429.05%	-3333.88%	-1685.91%	-1794.88%	-3036.69%	-3319.84%	-10249.73%	-3762.39%	-3254.23%	-4886.65%	-7807.07%	-305.87%	-1357.08%	-1885.94%	-1790.61%	-82.29%	-1672.75%	-1451.40%	-1919.91%	-83.43%	-Infinity%	-10371.29%	NaN%	-20972.18%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%
interest income	3,421,000	4,045,000	4,264,000	4,656,000	5,152,000	5,159,000	4,877,000	5,332,000	4,239,000	4,596,000	4,965,000	4,738,000	3,853,000	1,235,000	852,000	330,000	112,000	106,000	112,000	136,000	173,000
interest expense	-7,147,000	-7,297,000	-8,644,000	-8,516,000	-8,200,000	-8,706,000	-3,046,000	-3,319,000	-3,433,000	-2,321,000	-2,066,000	-2,003,000	-1,922,000	-2,005,000	-1,817,000	-1,581,000	-1,479,000	-1,135,000	-1,058,000	-804,000	-743,000
other income	-74,000
net income	-3,642,000	-28,862,000	-18,428,000	-16,375,000	-19,835,000	-25,352,000	-26,447,000	-67,383,000	-55,390,000	-51,973,000	-44,805,000	-49,227,000	-38,122,000	-42,635,000	-41,051,000	-28,117,000	-30,098,000	-32,017,000	-26,697,000	-29,574,000	-27,824,000	-23,787,000	-19,651,000	-15,824,000	-16,355,000	-29,070,000	-15,180,000	-14,239,000	-10,059,000	-7,300,000	-5,597,000	-6,934,000	-7,186,000	-7,429,000	-6,899,000	-6,405,000	-7,183,000	-3,576,000	-8,637,000	-8,842,000	27,185,000	-9,356,000	-9,315,000	-9,549,000	-8,734,000	-8,440,000	-8,254,000	-8,947,000	-11,897,000	-15,953,000	-18,326,000	-18,739,000	-31,854,000	-19,522,000	-21,088,000	-24,389,000	-59,362,000	-18,344,000	-17,031,000	-16,640,000	-18,391,000	-15,224,000	-19,758,000	-16,811,000	-17,632,000	-17,151,000	-13,564,000	-11,045,000	-12,834,000	-13,985,000	1,167,000	-5,585,000	-9,837,000	-9,257,000	-11,862,000	-3,082,000	-9,688,000	-10,302,000		-51,683,000	-5,581,750	-5,107,000	-9,288,000	-7,932,000	-7,196,000	-9,008,000	-10,475,000
yoy	-81.64%	13.85%	-30.32%	-75.70%	-64.19%	-51.22%	-40.97%	36.88%	45.30%	21.90%	9.14%	75.08%	26.66%	33.16%	53.77%	-4.93%	8.17%	34.60%	35.86%	86.89%	70.13%	-18.17%	29.45%	11.13%	62.59%	298.22%	171.22%	105.35%	39.98%	-1.74%	-18.87%	8.26%	0.04%	107.75%	-20.12%	-27.56%	-126.42%	-61.78%	-7.28%	-7.40%	-411.25%	10.85%	12.85%	6.73%	-26.59%	-47.09%	-54.96%	-52.25%	-62.65%	-18.28%	-13.10%	-23.17%	-46.34%	6.42%	23.82%	46.57%	222.78%	20.49%	-13.80%	-1.02%	4.30%	-11.24%	45.66%	52.20%	37.39%	22.64%	-1262.30%	97.76%	30.47%	51.07%	-109.84%	81.21%	1.54%	-10.14%		-94.04%	73.57%	101.72%		551.58%	-22.43%	-43.31%	-11.33%
qoq	-87.38%	56.62%	12.54%	-17.44%	-21.76%	-4.14%	-60.75%	21.65%	6.57%	16.00%	-8.98%	29.13%	-10.59%	3.86%	46.00%	-6.58%	-5.99%	19.93%	-9.73%	6.29%	16.97%	21.05%	24.18%	-3.25%	-43.74%	91.50%	6.61%	41.55%	37.79%	30.43%	-19.28%	-3.51%	-3.27%	7.68%	7.71%	-10.83%	100.87%	-58.60%	-2.32%	-132.53%	-390.56%	0.44%	-2.45%	9.33%	3.48%	2.25%	-7.75%	-24.80%	-25.42%	-12.95%	-2.20%	-41.17%	63.17%	-7.43%	-13.53%	-58.91%	223.60%	7.71%	2.35%	-9.52%	20.80%	-22.95%	17.53%	-4.66%	2.80%	26.45%	22.81%	-13.94%	-8.23%	-1298.37%	-120.90%	-43.22%	6.27%	-21.96%	284.88%	-68.19%	-5.96%			825.93%	9.30%	-45.02%	17.10%	10.23%	-20.12%	-14.00%
net income margin %	-7.03%	-84.97%	-39.02%	-33.39%	-50.08%	-344.26%	-93.55%	-7639.80%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-70.01%	-Infinity%	-Infinity%	76.87%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-2508.33%	-14096.92%	-1494.34%	-12690.84%	-8873.64%	-4564.50%	-1620.53%	-5406.38%	-3359.71%	-1701.40%	-1812.64%	-3039.83%	-3081.78%	-10796.72%	-3786.26%	-3241.18%	-4673.30%	-6850.51%	-235.65%	-1135.75%	-1573.12%	127.40%	-137.36%	-1360.58%	-1177.74%	-1762.56%	-65.98%	-Infinity%	-10200.00%	NaN%	-20839.92%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%
basic and diluted net loss per share	-0.01	-0.05	-0.03	-0.02	-0.03	-0.04	-0.04	-0.1	-0.09	-0.09	-0.08	-0.09	-0.07	-0.11	-0.1	-0.07	-0.09	-0.09	-0.08	-0.09	-0.09	-0.08	-0.06	-0.06	-0.08	-0.15	-0.08	-0.08	-0.05	-0.04	-0.03	-0.04	-0.04	-0.033	-0.04	-0.04	-0.05		-0.05	-0.06		-0.06	-0.06	-0.06	-0.06	-0.06		-0.07	-0.09	-0.13	-0.14	-0.15																													-0.19	-0.15
weighted-average shares used for eps calculation	669,375																																																																								66,166,827	65,932,548	57,225,184	55,301,745	54,175,184			40,449,815		33,189,213	29,452,031	24,935,574	24,737,635	24,674,456	24,490,391
other income and (expense)		-76,250	-161,000	-61,000	-83,000	-47,000	-63,000	-63,000	-62,000	-16,000	-92,000	-11,000	39,000	229,000	-138,000	1,110,000	-56,000	-6,000	-77,000	-17,000	1,200,000
shares used in computing basic and diluted net loss per share		166,599,227.5	667,101,756	666,170,358	665,905,469	6,099,635	662,158,182	653,904,978	603,493,451	8,199,828	579,508,305	547,280,946	544,459,004	125,797	405,237,474	403,868,713	332,066,889	1,079,051	328,934,491	327,026,907	323,638,696	15,899,486	318,799,174	246,966,143	200,222,092	2,792,690	189,123,647	186,556,082	186,393,128	3,317,243	184,301,986	174,475,244	160,525,947	39,796,713.25	159,216,642	159,182,367	159,161,550		158,998,931	158,896,038		158,066,910	157,547,568	156,843,989	156,706,196	143,465,818		128,162,993	127,982,931	127,236,993	126,891,909	126,372,846
total operating expenses				61,490,000	56,307,000	67,587,000	56,486,000	70,215,000	56,438,000	54,312,000	47,776,000	51,980,000	40,113,000	42,054,000	40,245,000	28,049,000	28,798,000	32,022,000	25,783,000	28,996,000	28,591,000	23,316,000	20,123,000	16,805,000	16,922,000	30,179,000	16,103,000	15,325,000	11,358,000	9,964,000	6,970,000	7,450,000	7,755,000	7,977,000	7,407,000	6,905,000	8,031,000	8,985,000	9,122,000	9,826,000	8,343,000	9,730,000	9,993,000	10,067,000	9,004,000	9,205,000	8,914,000	9,077,000	12,750,000	16,513,000	18,609,000	20,172,000	30,659,000	20,156,000	21,878,000	25,861,000	60,709,000	18,749,000	17,877,000	17,395,000	18,977,000	16,894,000	18,940,000	17,149,000	18,247,000	18,301,000	15,656,000	19,023,000	16,465,000	17,655,000	17,318,000	7,412,000	12,817,000	12,194,000	13,594,000	8,568,000	10,422,000	10,576,000		52,259,000
operating expenses:
general and administrative									27,065,000	21,401,000	18,350,000	16,490,000	12,894,000	13,844,000	15,642,000	7,443,000	6,699,000	7,872,000	7,256,000	7,059,000	7,478,000	7,088,000	6,510,000	5,960,000	6,120,000	5,256,000	4,994,000	5,191,000	5,452,000	4,883,000	4,263,000	4,246,000	5,315,000	5,454,000	4,770,000	4,406,000	4,657,000	4,666,000	4,547,000	4,793,000	4,334,000	3,977,000	4,600,000	4,073,000	3,853,000	3,994,000	3,460,000	3,432,000	4,751,000	4,829,000	5,832,000	5,065,000	5,538,000	3,811,000	5,334,000	9,106,000	4,684,000	5,021,000	4,488,000	3,850,000	3,638,000	3,499,000	3,828,000	3,378,000	4,018,000	4,093,000	4,042,000	4,012,000	4,139,000	3,557,000	4,129,000	1,724,000	2,114,000	2,868,000	1,411,000	1,744,000	3,949,000	1,676,000		1,391,000	838,250	845,000	1,166,000	1,342,000	1,314,000	1,453,000	1,596,000
license fees and royalties														103,000	297,000	73,000		1,040,000	109,000	107,000	137,000	50,000	108,000	43,000	52,000	171,000	131,000	101,000	57,000	375,000	165,000	208,000	318,000	191,000	163,000	174,000	537,000	5,108,000	211,000	749,000	363,000	251,000	537,000	160,000	341,000	474,000	181,000	112,000	765,000	636,000	130,000	1,254,000	251,000	220,000	312,000	1,355,000	453,000	343,000	776,000	693,000							111,000	4,612,000	1,130,000	585,000	623,000	4,141,000	524,000	675,000	606,000	4,620,000	59,000	101,000		248,000	236,750	472,000	249,000	226,000	200,000	96,000	111,000
change in fair value of equity investment																						-49,000	-118,000	422,000	-195,000		-195,000	-98,000	98,000	-271,000	205,000	-350,000	-125,000
interest and other income																						433,250	504,000	475,000	754,000	925,000	1,021,000	1,113,000	1,162,000	1,120,000	1,060,000	717,000	394,000	375,000	363,000	346,000	332,000	322,000	293,000	256,000	187,000	145,000	149,000	91,000	99,000	83,000	699,000	56,000	81,000	140,000	165,000	176,000	204,000	237,000	287,000	296,000	1,426,000	223,000	194,000	202,000	246,000	240,000	363,000	525,000	1,029,000	1,197,000	1,423,000	2,384,000	2,772,000	2,843,000	2,792,000	-1,706,000	2,283,000	2,189,000	1,105,000	998,000	847,000	348,000		498,000	239,250	287,000	394,000	276,000	434,000	665,000	871,000
interest and other expense																						-6,250	-22,000										-18,000	-18,000	-18,000																	-23,000																													-142,750	-157,000
other expense																								41,000	-44,000	13,000	-34,000	-30,000	-18,000	-20,000	-57,000	-59,000
collaboration revenue																																									35,000,000
unrealized gain on derivatives																																											16,000	289,000		224,000			25,000		8,000		142,500	291,000	240,000		33,250	-97,000	172,000	58,000	-71,750	966,000	-1,330,000		184,750	-162,000	495,000	931,000	-247,000	-36,000	14,805,000
net income per share																																																													-0.148	-0.17
basic																																						-0.02			0.17
diluted																																						-0.02			0.17
shares used in computing net income per share:
basic																																						159,140,254			158,151,747
diluted																																						159,140,254			162,669,681
unrealized gain (loss) on derivatives
unrealized loss on derivatives
basic and diluted net income per share																																															-0.06						-0.13	-0.16	-0.17	-0.2				-0.18				-0.2								-0.108	-0.15	-0.14	-0.21	-0.06	-0.18	-0.23		-1.28			-0.32	-0.32	-0.29	-0.37	-0.43
shares used in computing basic and diluted net income per share																																															128,293,074									123,098,728				95,012,100				84,160,889
revenues from collaborative agreements																																																							150,000	150,000	163,250	203,000	225,000	225,000							87,000	75,000			293,000	-75,000	199,000	111,000	67,000	51,000					18,000		36,000	36,000	18,000	15,000	515,000
losses recognized under equity method investment																																																							-168,000	-335,000	-1,212,000	-243,000	-496,000	-396,000	-164,000			-656,000
unrealized gain on fair value of derivatives																																																				26,000				39,000								77,000
research and development (including amounts
for related parties: three months - 2011-none;
2010-53; nine months – 2011-none; 2010-697)																																																					12,411,000	16,345,000
shares used in computing basic and diluted net income
per share																																																					31,064,924.5	125,101,177	124,579,190
research and development (including amounts for
related parties: three months - 2011-none; 2010-
317; six months – 2011-none; 2010-644)																																																							16,544,000
for related parties: 2011-none, 2010-327)																																																								16,755,000
related parties: three months – 2010-53; 2009-
397; nine months – 2010-697; 2009-1,328)																																																									10,165,500	13,728,000
deemed dividend on derivatives																																																															-190,000					-5,420,000			-3,661,000
net income applicable to common stockholders																																																									-59,362,000	-18,344,000	-17,031,000		-12,995,750	-15,224,000	-19,948,000		-11,097,250	-17,151,000	-13,564,000	-7,328,250	-12,834,000	-13,985,000	-2,494,000
basic and diluted net income per share applicable to
common stockholders																																																									97,601,520.54	-0.19	-0.18
per share applicable to common stockholders																																																									24,100,069	97,476,668	96,712,059
related parties: three months - 2010-317; 2009-
502; six months – 2010-644; 2009-931)																																																											13,389,000
for related parties: 2010-327, 2009-429)																																																												13,545,000
revenues from collaborative
agreements (including amounts from related
parties: three months - 2009-none, 2008-20;
nine months - 2009-none, 2008-79)																																																													56,250	225,000
license fees and royalties (including amounts
from related parties: three months -
2009-none, 2008-none; nine months -
2009-none, 2008-1,500)																																																													224,000	269,000
research and development (including
amounts for related parties:
three months - 2009-397, 2008-184;
nine months - 2009-1,328, 2008-502)																																																													10,569,500	13,395,000
basic and diluted net income per share applicable
to common stockholders
net income per share																																																													-0.148	-0.17
shares used in computing net income per share
applicable to common stockholders																																																													708,196	89,402,642	88,547,553
parties: three months - 2009-none; 2008-
33; six months - 2009-none; 2008-59)
from related parties: three months - 2009-none;
2008-none; six months - 2009-none; 2008-
1,500)																																																															183,000
amounts for related parties: three months -
2009-502; 2008-169; six months - 2009-
931; 2008-318)																																																															15,112,000
losses recognized under equity method
investment
stockholders																																																															-0.23		-62,020,999.43	-0.22
revenues from collaborative agreements (including amounts from
related parties: 2009-none, 2008-26)
license fees and royalties (including amounts from related
parties: 2009-none, 2008-1,500)																																																																444,000
research and development (including amounts for related
parties: 2009-429, 2008-149)																																																																13,771,000
revenues from collaborative agreements (including
amounts from related parties: three months - 2008-20;
2007-none; nine months - 2008-79; 2007-448)																																																																	60,000	74,000
license fees and royalties (including amounts from
related parties: three months - 2008-none; 2007-none;
nine months - 2008-1,500; 2007-none)																																																																	504,750	293,000
related parties: three months - 2008-184; 2007-70;
nine months - 2008-502; 2007-569)																																																																	9,858,750	14,208,000
loss recognized under equity method investment																																																																	-57,250	-229,000
basic and diluted net income per share applicable to common
shares used in computing basic and diluted net income per
share applicable to common stockholders																																																																	19,460,376.25	78,752,645
basic and diluted net income per share applicable to common stockholders																																																																			-0.17	-0.1	-0.17	-0.19	-0.03
shares used in computing basic and diluted net income per share applicable to common stockholders																																																																			78,142,176	18,433,289.75	75,324,687	74,077,733	71,797,056
equity in losses in joint venture
acquired in-process research technology																																																																																45,150,000
equity in losses of joint venture																																																																												-12,000
acquired in-process research
technology
debenture conversion expense																																																																																	-194,750		-779,000
computing basic and diluted net
loss per share																																																																														45,442,854

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-09-30	2006-06-30	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-03-31	2003-09-30	2003-06-30	2003-03-31	2002-09-30	2002-06-30	2002-03-31

assets
current assets:
cash and cash equivalents	68,895,000	77,560,000	78,117,000	77,734,000	83,745,000	79,016,000	60,344,000	116,945,000	189,761,000	70,023,000	30,709,000	56,903,000	112,777,000	56,845,000	61,103,000	76,057,000	31,325,000	34,871,000	29,036,000	57,282,000	31,537,000	9,925,000	44,956,000	22,865,000	20,294,000	13,644,000	20,751,000	17,710,000	6,800,000	10,575,000	12,729,000	19,127,000	7,912,000	16,335,000	9,904,000	6,606,000	14,861,000	5,883,000	8,199,000	12,802,000	16,823,000	15,798,000	10,182,000	7,600,000	9,520,000	11,324,000	9,591,000	8,834,000	15,505,000	16,008,000	14,123,000	19,031,000	16,105,000	33,975,000	32,019,000	35,412,000	45,972,000	34,490,000	37,315,000	35,900,000	34,601,000	97,869,000	101,371,000	125,601,000	109,348,000	121,807,000	127,080,000	146,025,000	152,767,000	126,943,000	145,722,000	104,556,000	68,875,000	119,303,000	21,609,000	7,530,000	9,846,000	10,185,000	6,529,000	8,042,000	10,956,000	7,089,000	15,428,000	28,245,000	19,609,000
restricted cash	1,884,000	1,880,000	1,876,000	1,870,000	1,865,000	1,860,000	1,854,000	1,123,000	1,119,000	1,115,000	536,000	535,000	365,000	364,000	364,000	364,000	364,000	364,000	363,000	363,000	363,000	363,000	363,000	363,000	270,000	270,000	270,000	270,000	270,000	269,000	269,000	269,000	268,000	268,000	268,000	268,000	268,000	268,000	267,000	267,000	266,000	266,000	266,000	265,000	795,000	795,000	795,000	795,000	794,000	794,000	794,000	793,000	793,000	793,000	793,000	792,000	792,000	792,000	792,000	791,000	791,000	791,000	791,000	817,000	816,000	832,000	1,082,000	2,440,000	530,000	530,000	530,000	530,000	530,000	905,000	905,000	530,000	530,000	530,000	530,000	530,000	530,000	530,000	530,000	530,000	530,000
marketable securities	243,506,000	280,359,000	302,415,000	310,247,000	313,132,000	327,550,000	279,430,000	245,789,000	253,288,000	263,676,000	282,818,000	314,475,000	267,964,000	115,901,000	133,684,000	143,230,000	135,345,000	148,851,000	147,084,000	140,959,000	179,490,000	186,350,000	182,667,000	195,881,000	111,822,000	125,681,000	117,860,000	134,778,000	145,180,000	152,714,000	153,622,000	141,800,000	81,868,000	78,351,000	86,991,000	88,239,000	84,432,000	102,655,000	102,402,000	96,846,000	102,857,000	122,214,000	135,655,000				56,617,000	61,966,000	63,534,000													80,748,000	86,475,000	74,084,000	53,491,000	52,537,000	58,571,000	59,979,000	54,875,000	90,011,000	75,504,000	69,493,000	112,276,000	79,536,000	104,525,000	116,955,000	110,118,000	80,015,000	92,673,000
accounts receivable	41,882,000	36,987,000	35,361,000	36,608,000	31,166,000	35,946,000	28,007,000	874,000
interest and other receivables	2,213,000	2,239,000	2,295,000	2,755,000	2,817,000	2,853,000	2,082,000	2,252,000	1,629,000	1,655,000	14,754,000	1,187,000	1,596,000	3,144,000	22,223,000	4,254,000	5,239,000	1,763,000	610,000	714,000	759,000	722,000	989,000	822,000	701,000	802,000	795,000	838,000	976,000	1,168,000	778,000	773,000	569,000	436,000	514,000	457,000	597,000	5,404,000	586,000	624,000	1,238,000	1,505,000	1,190,000	787,000	1,256,000	1,439,000	555,000	480,000	921,000	842,000	932,000	866,000	1,398,000	1,569,000	1,630,000	1,676,000	1,799,000	1,047,000	1,390,000	1,359,000	1,318,000	1,041,000	481,000	545,000	882,000	186,000	305,000		1,105,000	1,259,000	856,000	1,488,000	1,883,000	1,367,000	1,674,000	1,638,000	1,550,000	960,000	5,477,000	681,000	665,000	354,000	1,162,000	803,000	1,016,000
inventory	133,287,000	116,636,000	95,422,000	69,125,000	56,222,000	38,714,000	20,283,000	774,000
prepaid and other current assets	6,864,000	4,610,000				5,053,000			5,712,000	4,879,000	6,268,000	4,179,000	4,321,000	3,992,000	4,696,000	3,470,000	3,651,000	1,357,000	2,262,000	2,444,000	3,115,000	2,497,000	2,886,000	812,000	1,068,000	1,211,000	2,445,000	1,166,000
total current assets	498,531,000	520,271,000	522,342,000	505,595,000	495,769,000	490,992,000	398,057,000	373,308,000	451,509,000	341,348,000	335,085,000	377,279,000	387,023,000	180,246,000	222,070,000	227,375,000	175,924,000	187,206,000	179,355,000	201,762,000	215,264,000	199,857,000	231,861,000	220,743,000	134,155,000	141,608,000	142,121,000	154,762,000	155,949,000	166,058,000	168,874,000	162,270,000	91,129,000	95,970,000	98,563,000	102,066,000	106,563,000	115,056,000	111,702,000	110,955,000	122,015,000	140,198,000	147,897,000	128,192,000	142,592,000	147,676,000	68,402,000	72,431,000	81,576,000	103,046,000	120,845,000	122,522,000	125,625,000	147,304,000	157,194,000	170,203,000	195,017,000	137,474,000	130,948,000	133,234,000	117,779,000	184,683,000	193,225,000	204,801,000	168,246,000	179,080,000	192,917,000	213,372,000	212,000	222,631,000	224,955,000	178,141,000	186,374,000	204,030,000	132,172,000	129,477,000	124,777,000	95,128,000	109,366,000
noncurrent marketable securities	26,686,000	41,289,000	39,063,000	42,743,000	58,795,000	94,519,000	37,312,000	66,505,000	20,782,000	43,298,000	67,821,000	28,281,000	28,100,000				10,945,000	28,651,000	39,362,000	40,521,000	33,289,000	63,387,000	45,768,000	46,223,000	1,029,000	19,651,000	20,404,000	9,497,000	17,871,000	18,582,000	18,143,000	20,250,000	13,184,000	14,241,000	15,560,000	22,076,000	22,126,000	21,005,000	25,523,000	31,976,000	31,821,000	18,734,000	17,739,000
property and equipment	1,000,000	884,000	973,000	1,189,000	1,147,000	1,310,000	1,595,000	1,626,000	1,681,000	1,177,000	1,231,000	1,147,000	1,066,000	793,000	733,000	641,000	643,000	650,000	608,000	590,000	620,000	658,000	689,000	734,000	749,000	408,000	348,000	100,000	89,000	59,000	66,000	71,000	86,000	102,000	121,000	140,000	158,000	170,000	191,000	212,000	183,000	151,000	171,000	63,000	60,000	77,000	116,000	566,000	866,000	1,431,000	1,240,000	1,074,000	1,241,000	2,247,000	2,514,000	2,794,000	3,088,000	3,217,000	3,499,000	3,934,000	3,938,000	4,265,000	4,745,000	4,483,000	4,386,000	4,240,000	4,092,000	4,075,000	3,709,000	3,868,000	3,064,000	2,526,000	2,623,000	2,326,000	2,087,000	1,975,000	2,089,000	2,173,000	1,558,000	1,809,000	1,983,000	2,167,000	2,788,000	3,166,000	3,521,000
operating leases, right-of-use assets	1,959,000	2,151,000	2,339,000	2,523,000	2,704,000	2,881,000	3,055,000	3,225,000	3,392,000	3,556,000	3,683,000	3,841,000	3,995,000	4,147,000	4,296,000	4,442,000	4,586,000	4,727,000	4,892,000	5,029,000	5,163,000	5,295,000	5,425,000	5,492,000	5,827,000	2,497,000
deposits and other assets	5,944,000	5,945,000	2,665,000	3,148,000	4,035,000	4,079,000	4,931,000	4,735,000	4,710,000	4,697,000	5,197,000	4,748,000	4,693,000	5,389,000	5,507,000	5,703,000	6,323,000	4,800,000	4,880,000	4,273,000	4,272,000	1,531,000	2,050,000	1,622,000	1,129,000	1,353,000																		191,000	191,000	191,000	195,000	414,000	410,000	825,000	825,000	879,000	1,048,000	932,000	920,000	230,000	210,000	190,000	284,000	212,000	296,000	441,000	343,000	343,000	693,000	1,969,000	702,000	695,000	693,000	693,000	594,000	596,000	640,000	520,000	170,000	170,000	175,000	202,000	231,000	227,000	227,000	240,000	254,000	340,000	265,000
liabilities and stockholders' equity
current liabilities:
accounts payable	12,720,000	11,257,000	11,111,000	8,226,000	8,032,000	8,595,000	13,734,000	5,620,000	9,992,000	6,161,000	13,684,000	7,673,000	3,383,000	10,190,000	8,183,000	4,521,000	6,245,000	6,687,000	4,714,000	3,758,000	4,459,000	6,919,000	3,739,000	3,797,000	3,376,000	1,181,000	2,031,000	1,210,000	913,000	982,000	190,000	458,000	502,000	503,000	261,000	205,000	308,000	271,000	235,000	396,000	574,000	957,000	1,180,000	2,365,000	1,223,000	1,520,000	1,547,000	1,176,000	1,669,000	3,014,000	3,429,000	2,666,000	2,980,000	4,006,000	3,471,000	3,343,000	3,462,000	1,958,000	1,715,000	1,807,000	2,176,000	2,008,000	2,453,000	1,899,000	2,414,000	2,108,000	2,443,000	2,857,000	1,990,000	4,118,000	3,342,000	1,435,000	1,572,000	3,067,000	1,848,000	1,388,000	2,535,000	1,667,000	798,000	1,212,000	1,259,000	1,797,000	847,000	861,000	785,000
accrued compensation and benefits	9,488,000	30,497,000	16,388,000	11,336,000	9,603,000	22,808,000	15,180,000	11,382,000	6,794,000	13,759,000	10,837,000	8,232,000	4,906,000	11,534,000	7,637,000	5,613,000	3,682,000	8,099,000	6,615,000	5,216,000	3,446,000	8,218,000	5,554,000	4,204,000	2,674,000	4,830,000	3,443,000	2,756,000	1,661,000	2,642,000	1,833,000	1,531,000	1,100,000	3,385,000	2,651,000	2,056,000	1,489,000	2,205,000	2,311,000	1,619,000	2,248,000	1,731,000	2,135,000	2,685,000	2,186,000	1,556,000	2,886,000	2,046,000	1,664,000	3,907,000	3,421,000	1,774,000	3,029,000
operating lease liabilities	1,007,000	1,000,000	994,000	987,000	981,000	974,000	968,000	961,000	955,000	949,000	943,000	786,000	931,000	925,000	919,000	913,000	907,000	901,000	895,000	889,000	883,000	878,000	872,000	856,000	828,000	354,000
liability related to sale of future royalties	19,390,000	17,448,000	19,291,000	17,440,000	15,532,000	20,372,000
accrued liabilities	30,965,000	51,340,000	39,928,000	26,294,000	28,886,000	35,549,000	36,489,000	38,660,000	33,891,000	40,308,000	41,862,000	45,036,000	34,691,000	33,100,000	53,111,000	30,670,000	35,796,000	29,834,000	26,246,000	27,150,000	19,764,000	14,925,000	13,989,000	10,285,000	10,037,000	7,528,000	4,831,000	3,237,000	1,037,000	1,317,000				926,000	1,112,000	856,000	1,054,000	1,432,000	1,126,000	1,071,000	727,000	933,000	1,375,000	2,018,000	1,057,000	1,286,000	1,985,000	1,358,000	2,591,000	4,171,000	4,378,000	4,379,000	3,641,000	3,005,000	3,066,000	3,536,000	2,644,000	1,509,000	1,485,000	1,925,000							2,419,000		3,721,000	3,398,000	2,365,000	1,367,000	1,160,000	1,008,000	862,000	580,000	822,000	677,000	648,000	906,000	1,082,000	905,000	1,762,000	1,529,000	1,434,000
total current liabilities	73,570,000	111,542,000	87,712,000	64,283,000	63,034,000	88,298,000	137,933,000	103,540,000	123,158,000	108,070,000	89,386,000	72,569,000	43,911,000	76,694,000	82,809,000	46,879,000	46,630,000	45,521,000	38,470,000	37,013,000	28,552,000	30,940,000	24,154,000	19,142,000	16,916,000	28,162,000	11,862,000	9,181,000	6,253,000	7,551,000	4,467,000	4,905,000	4,385,000	6,516,000	5,970,000	11,274,000	11,596,000	7,319,000	7,111,000	6,658,000	6,125,000	40,727,000	40,632,000	7,069,000	4,756,000	4,516,000	6,837,000	5,004,000	6,793,000	11,256,000	11,992,000	10,274,000	13,444,000	10,003,000	9,270,000	9,363,000	40,849,000	7,625,000	6,813,000	6,805,000	7,455,000	9,359,000	10,414,000	7,759,000	7,711,000	8,548,000	8,579,000	12,717,000	11,459,000	13,436,000	10,916,000	5,691,000	5,551,000	8,767,000	5,613,000	5,142,000	8,458,000	7,635,000	7,040,000
noncurrent operating lease liabilities	1,226,000	1,445,000	1,658,000	1,865,000	2,069,000	2,266,000	2,458,000	2,645,000	2,829,000	3,006,000	3,179,000	3,498,000	3,512,000	3,671,000	3,826,000	3,977,000	4,125,000	4,267,000	4,405,000	4,540,000	4,672,000	4,799,000	4,922,000	4,991,000	5,159,000	2,200,000
noncurrent liability related to sale of future royalties	110,383,000	112,134,000	110,041,000	110,528,000	110,381,000	104,421,000
noncurrent debt	119,833,000	119,547,000	119,264,000	118,991,000	118,728,000	118,476,000	12,275,000	36,519,000	11,219,000	35,051,000	29,838,000	40,802,000	51,399,000	30,212,000	37,799,000	45,258,000	50,179,000	49,830,000	34,669,000	34,416,000	24,222,000	24,042,000
total liabilities	305,012,000	344,668,000				313,461,000				146,127,000				110,577,000				99,618,000				59,781,000	52,961,000
commitments and contingencies
stockholders' equity:
preferred stock, 0.001 par value
common stock	641,000		638,000	638,000	637,000		603,000	601,000	591,000		542,000	522,000	509,000		382,000	378,000	324,000		321,000	321,000	318,000		310,000	310,000	200,000		193,000	187,000	186,000		186,000	183,000	161,000		159,000	159,000	159,000	159,000	159,000	159,000	158,000	158,000	158,000	157,000	157,000	157,000	129,000	130,000	130,000	131,000	131,000	132,000		132,000	131,000	129,000		103,000	99,000	97,000		92,000	91,000	89,000		79,000	79,000		75,000	75,000	73,000	66,000	66,000	65,000	55,000	54,000		45,000	45,000	33,000	33,000	25,000	25,000	25,000	24,000
additional paid-in capital	2,088,141,000	2,080,804,000	2,074,640,000	2,067,327,000	2,059,473,000	2,051,794,000	2,037,653,000	2,027,173,000	1,997,709,000	1,844,988,000	1,836,818,000	1,799,841,000	1,777,470,000	1,493,469,000	1,479,417,000	1,472,407,000	1,399,713,000	1,398,006,000	1,390,940,000	1,388,909,000	1,384,262,000	1,366,188,000	1,364,194,000	1,362,373,000	1,217,105,000	1,214,835,000	1,202,902,000	1,192,338,000	1,190,651,000	1,189,194,000	1,187,557,000	1,176,823,000	1,092,931,000	1,089,684,000	1,086,578,000	1,084,440,000	1,082,270,000	1,078,170,000	1,075,922,000	1,073,515,000	1,067,712,000	1,065,352,000	1,062,782,000	1,056,543,000	1,054,383,000	1,052,028,000	945,241,000	943,518,000	942,192,000	938,080,000	936,719,000	935,069,000	932,066,000	928,898,000	925,098,000	920,706,000	881,358,000	783,865,000	775,432,000	767,831,000	750,158,000	741,940,000	733,151,000	727,346,000	675,227,000	668,500,000	664,104,000	650,437,000	633,508,000	628,703,000	619,703,000	573,868,000	572,881,000	560,810,000	481,565,000	476,554,000	458,965,000	418,578,000	414,312,000
accumulated deficit	-1,859,483,000	-1,855,841,000	-1,826,979,000	-1,808,551,000	-1,792,176,000	-1,772,341,000	-1,746,989,000	-1,720,542,000	-1,653,159,000	-1,597,769,000	-1,545,796,000	-1,500,991,000	-1,451,764,000	-1,413,642,000	-1,371,007,000	-1,329,956,000	-1,301,839,000	-1,271,741,000	-1,239,724,000	-1,213,027,000	-1,183,453,000	-1,155,629,000	-1,131,842,000	-1,112,191,000	-1,096,367,000	-1,080,012,000	-1,050,942,000	-1,035,762,000	-1,021,523,000	-1,011,464,000	-1,004,164,000	-998,567,000	-991,633,000	-985,840,000	-978,411,000																	-804,242,000	-785,503,000	-753,649,000	-734,127,000	-713,039,000	-688,650,000	-629,282,000	-610,938,000	-593,907,000	-577,267,000	-558,876,000	-543,652,000	-523,704,000	-506,893,000	-489,261,000	-472,110,000	-444,872,000	-428,407,000	-415,573,000	-401,588,000	-397,703,000	-387,866,000	-360,703,000	-348,841,000	-345,759,000	-336,071,000	-326,596,000	-307,349,000	-248,110,000	-243,003,000	-233,715,000	-218,554,000	-211,358,000	-202,350,000
accumulated other comprehensive income	-191,000	269,000																																				25,000	90,000	40,000									18,000	82,000											-406,000	-118,000	-29,000	43,000	40,000	-68,000	-109,000	33,000															-590,000	-467,000	-361,000
total stockholders' equity	229,108,000	225,872,000	248,707,000	259,531,000	268,238,000	280,320,000	292,284,000	306,695,000	344,868,000	247,949,000	290,614,000	298,427,000	326,055,000	79,998,000	108,172,000	142,047,000	97,487,000	126,416,000	151,553,000	176,206,000	201,162,000	210,947,000	232,832,000	250,681,000	120,814,000	135,155,000	152,392,000	157,044,000	169,413,000	177,733,000	183,467,000	178,362,000	101,128,000	103,797,000	108,274,000
preferred stock, 0.001 par value...
common stock, 0.001 par value...		640,000				606,000				545,000				390,000				324,000				310,000				200,000				186,000				160,000
prepaid expenses and other current assets			6,856,000	7,256,000	6,822,000		6,057,000	5,551,000
accumulated other comprehensive gain			408,000			261,000												-173,000	16,000	3,000	35,000	78,000	170,000	189,000	-124,000	132,000	239,000	281,000	99,000
accumulated other comprehensive loss				117,000	304,000		1,017,000	-537,000	-273,000	185,000	-950,000	-945,000	-160,000	-219,000	-620,000	-782,000	-711,000													-183,000	-112,000	-77,000	-331,000	-207,000	-52,000																	-46,000	-91,000	-174,000	-42,000	-139,000	-96,000	-16,000	-271,000	-276,000									-37,000	-156,000	-215,000	-318,000	-466,000	-711,000	-731,000	-902,000	-623,000	-716,000	-357,000	-470,000	-475,000	-441,000
debt							71,562,000	46,917,000	71,526,000	46,893,000	22,060,000	10,842,000		20,945,000	12,959,000	5,162,000
amount due to janssen biotech, inc.																									1,000	14,269,000	1,208,000	1,576,000	2,071,000	2,610,000
term loan																							23,885,000
operating lease, right-of-use asset																											349,000	402,000	571,000
other assets																											1,032,000	1,464,000	1,186,000	585,000	851,000	676,000	1,114,000
operating lease liability																											349,000	402,000	571,000
prepaid assets																													2,723,000	1,332,000	1,476,000	301,000	512,000	580,000	886,000	496,000	405,000	846,000	248,000	416,000	831,000	415,000	604,000	739,000	205,000	249,000	844,000	356,000	822,000	959,000	946,000																							2,784,000	3,320,000	2,681,000		3,371,000	4,090,000	1,389,000	969,000	3,357,000
accrued collaboration charges																															1,560,000	2,192,000	1,841,000	1,702,000	1,946,000	1,907,000	2,495,000	3,398,000	3,420,000	3,537,000	2,498,000	1,901,000	626,000
other accrued liabilities																															884,000	724,000	942,000
litigation settlement insurance recovery																																				6,000,000	6,000,000
liabilities and stockholders’ equity
litigation settlement payable																																				6,250,000	6,250,000
stockholders’ equity:
total stockholders’ equity																																				113,008,000	117,251,000	128,912,000	130,305,000	136,485,000	147,894,000	118,356,000	125,175,000	137,178,000	144,583,000	150,892,000	61,876,000	68,407,000	76,059,000	99,772,000	114,201,000	130,913,000	146,603,000	175,207,000	191,060,000	207,657,000	192,735,000	154,670,000	164,322,000	173,745,000	172,577,000	183,038,000	189,561,000	203,774,000	168,455,000	179,250,000	191,964,000	205,674,000	205,139,000	213,049,000	217,973,000	175,913,000	184,340,000	199,314,000	131,868,000	129,740,000	122,063,000	91,171,000	106,454,000
accrued restructuring charges																																						13,000	19,000	35,000	78,000	205,000	316,000			11,000	161,000	374,000	843,000	90,000	734,000	1,417,000	3,730,000
deferred revenue																																										35,000,000	35,000,000													175,000
fair value of derivatives																																												1,000	290,000	143,000	258,000	50,000	26,000	74,000	30,000	38,000	64,000	137,000	428,000	668,000	707,000	764,000	667,000	839,000	897,000	1,341,000	2,407,000	1,077,000	1,184,000	863,000	701,000	1,602,000	2,533,000	3,502,000	3,711,000
current portion of marketable securities																																												118,801,000	130,816,000	133,869,000				84,443,000	104,050,000	100,394,000	105,208,000	108,127,000	119,756,000	127,915,000	140,599,000	91,056,000	83,789,000	89,390,000	77,009,000
noncurrent portion of marketable securities																																												15,801,000	6,496,000	7,464,000				5,726,000	3,283,000	16,712,000	32,133,000	37,921,000	39,592,000	43,186,000	33,911,000	19,856,000	34,100,000	40,447,000	54,669,000
current portion of prepaid assets																																																				1,438,000	2,121,000	2,840,000	2,996,000	4,408,000	5,855,000	10,089,000	7,662,000	5,794,000	4,060,000				3,709,000	3,718,000	5,879,000	4,140,000	3,070,000	3,888,000	2,343,000	2,074,000	2,810,000				2,586,000
noncurrent portion of prepaid assets																																																							108,000	438,000	854,000	1,364,000	1,867,000	1,966,000	2,372,000	1,523,000	1,662,000	1,905,000	2,236,000	2,567,000	2,897,000	699,000	755,000	931,000	226,000	565,000	735,000				3,212,000
investments in licensees																																																							2,000	169,000	504,000	194,000	437,000	932,000	1,328,000	2,010,000		1,000	657,000
stock issuance obligation																																																									27,500,000
current portion of deferred revenue																																																									350,000	577,000	700,000	700,000	700,000	700,000			27,000	80,000	134,000	241,000	27,000	100,000	605,000	1,455,000	1,737,000	1,862,000	144,000	472,000	477,000	210,000	149,000	307,000	367,000	442,000	567,000	313,000	267,000
issued and outstanding at december 31, 2011 and 2010
131,443,148 and 122,616,729 shares issued and outstanding at
december 31, 2011 and 2010, respectively																																																					131,000
accrued compensation																																																						2,855,000	2,305,000	1,641,000	6,186,000	2,817,000	2,246,000	1,534,000	1,757,000	2,633,000	2,023,000	1,275,000	1,398,000	2,399,000	1,844,000	2,203,000	1,973,000	1,441,000	893,000	1,434,000	1,082,000	1,276,000	953,000	572,000	2,024,000	1,304,000	478,000	606,000	462,000	329,000	761,000	1,508,000	651,000
long-term debt																																																						3,194,000
noncurrent portion of deferred revenue																																																												175,000	350,000	525,000			52,000	58,000	65,000	78,000	85,000	91,000	98,000	442,000	698,000	1,674,000	458,000	665,000	707,000	751,000	781,000	872,000	923,000	1,002,000	1,063,000	996,000	1,046,000
issued and outstanding at december 31, 2010 and 2009
122,616,729 and 92,521,946 shares issued and outstanding at
december 31, 2010 and 2009, respectively																																																									123,000
accrued liabilities (including amounts for related parties:
2009-none, 2008-270)																																																													1,925,000	2,677,000
current portion of advance payment from related party for research and
development																																																																	440,000			1,300,000
issued and outstanding at december 31, 2009 and 2008
92,521,946 and 81,070,464 shares issued and outstanding at
december 31, 2009 and 2008, respectively																																																													92,000
current portion of prepaid and other assets																																																														4,234,000	4,107,000	3,754,000
current portion of advance payment from related party for
research and development																																																															127,000	199,000		738,000
2009-275, 2008-270)																																																															3,404,000
2009-497, 2008-270)																																																																3,309,000
2008-270, 2007-1,029)																																																																	2,248,000
noncurrent portion of advance payment from related party for research and
issued and outstanding at december 31, 2008 and 2007
81,070,464 and 76,062,439 shares issued and outstanding at
december 31, 2008 and 2007, respectively																																																																	81,000
2008-267, 2007-1,029)																																																																		2,360,000
noncurrent portion of advance payment from related party
for research and development
current portion of advance payment from related party for research and development																																																																			1,038,000		1,215,000	877,000
noncurrent portion of advance payment from related party for research and development																																																																					921,000	1,657,000
interest and other receivables (including amounts from related parties:
2007-none, 2006-293)																																																																				788,000
equity investments in licensees																																																																				55,000	100,000	110,000	148,000			330,000	325,000		489,000	330,000	274,000	427,000	367,000	347,000	314,000
2007-1,029, 2006-none)																																																																				4,514,000
issued and outstanding at december 31, 2007 and 2006
76,062,439 and 70,449,058 shares issued and outstanding at
december 31, 2007 and 2006, respectively																																																																				76,000
equity investments in licensees and joint ventures																																																																								218,000	217,000
intangible assets																																																																										565,000	754,000	942,000	1,131,000	1,671,000	3,103,000	4,535,000	5,251,000	5,967,000	7,400,000	8,116,000	8,832,000
current portion of equipment loans																																																																										82,000	112,000	129,000	146,000	162,000	169,000	189,000	220,000	281,000	528,000	565,000	710,000
current portion of research funding obligation																																																																										1,472,000	1,694,000	2,001,000	2,454,000	3,615,000	4,798,000	4,380,000	4,525,000	4,742,000	4,862,000	4,845,000	4,698,000
commitments
deferred compensation																																																																									-275,000	-147,000	-180,000	-207,000	-260,000	-140,000	-197,000	-131,000	-151,000	-173,000	-53,000	-114,000	-174,000
notes receivable from related parties																																																																										135,000	139,000	143,000	147,000	67,000	67,000	64,000	208,000	366,000	244,000	255,000	265,000
noncurrent portion of equipment loans																																																																												28,000	55,000	82,000	157,000	244,000	285,000	326,000	433,000	620,000	192,000
noncurrent portion of research funding obligation																																																																												295,000	590,000		243,000	1,672,000	2,394,000	3,108,000	4,544,000	5,266,000	5,980,000
equity investments in licensees and joint venture																																																																												484,000
fair value of warrants to purchase common stock
authorized; no shares issued and outstanding
authorized; 52,220,332 shares issued and outstanding																																																																													52,000
convertible debentures																																																																																		16,320,000	16,310,000	16,305,000	16,300,000
additional paid-in-capital																																																																																297,279,000	295,739,000	257,563,000	256,006,000	255,374,000	253,649,000
commitments stockholders’ equity:
short-term investments																																																																																			31,424,000	33,317,000	48,755,000
other current assets																																																																																			2,353,000	638,000	653,000
long-term investments																																																																																			6,258,000
equity investment in licensees																																																																																				455,000	597,000
redeemable common stock																																																																																					1,585,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2005-09-30	2005-06-30	2005-03-31	2004-03-31	2003-09-30	2003-06-30	2003-03-31	2002-09-30	2002-06-30	2002-03-31

cash flows from operating activities:
net loss	-3,642,000	-28,862,000	-18,428,000	-16,375,000	-19,835,000	-25,352,000	-26,447,000	-67,383,000	-55,390,000	-51,973,000	-44,805,000	-49,227,000	-38,122,000	-42,635,000	-41,051,000	-28,117,000	-30,098,000	-32,017,000	-26,697,000	-29,574,000	-27,824,000	-23,787,000	-19,651,000	-15,824,000	-16,355,000	-29,070,000	-15,180,000	-14,239,000	-10,059,000	-7,300,000	-5,597,000	-6,934,000	-7,186,000		-6,899,000	-6,405,000	-7,183,000		-8,637,000	-8,842,000		-9,356,000	-9,315,000	-9,549,000	-8,734,000	-8,440,000		-8,947,000	-11,897,000	-15,953,000	-18,326,000	-18,739,000
adjustments to reconcile net loss to net cash from operating activities:
depreciation and amortization	134,000	87,000	128,000	128,000	131,000	142,000	31,000	262,000	111,000	114,000	108,000	121,000	99,000	80,000	79,000	72,000	57,000	61,000	53,000	53,000	48,000	49,000	49,000	33,000	27,000	29,000	9,000	11,000	15,000	14,000	14,000	15,000	16,000	19,000	19,000	18,000	20,000	21,000	21,000	21,000	17,000	13,000	9,000	9,000	14,000	15,000	93,000	122,000	142,000	193,000	214,000	251,000	344,000	402,000	416,000	418,000	401,000	404,000	407,000	397,000	407,000	462,000	453,000	431,000	408,000	464,000	526,000	511,000	353,000	277,000	249,000	250,000	230,000	233,000	240,000	251,000
accretion and amortization on investments	-1,069,000	-1,444,000	-1,529,000	-1,738,000	-2,210,000	-2,402,000	-2,388,000	-2,526,000	-2,367,000	-2,815,000	-3,372,000	-3,236,000	-1,727,000	-956,000	-313,000	108,000	196,000	287,000	359,000	362,000	416,000	431,000	421,000	90,000	-124,000	-251,000	-325,000	-476,000	-482,000	-457,000	-410,000	-135,000	24,000	60,000	69,000	89,000	55,000	68,000	155,000	284,000	494,000	547,000	629,000	765,000	850,000	606,000	301,000	319,000	328,000	542,000	595,000	669,000	889,000	1,102,000	1,205,000	1,226,000	765,000	989,000	905,000	909,000	505,000	257,000	173,000	-9,000	-88,000	-205,000	-599,000	-994,000	-917,000	-717,000	-688,000	-395,000	331,000	620,000	584,000	944,000
amortization of debt issuance costs/debt discounts	286,000		273,000	262,000	253,000		402,000	690,000	802,000		255,000	245,000	242,000				349,000
non-cash interest expense on liabilities for sales of future royalties	3,912,000	3,905,000	5,163,000	5,079,000	4,801,000
stock-based compensation expense	4,913,000
amortization of right-of-use assets	192,000	188,000	184,000	181,000	177,000	174,000	170,000	167,000	164,000	127,000	158,000	154,000	152,000	149,000	146,000	144,000	141,000	165,000	137,000	134,000	132,000		67,000	336,000	244,000
increase in allowance for doubtful accounts		-46,000	-25,000	-110,000	131,000
changes in assets and liabilities:
inventory	-16,651,000	-21,214,000	-26,298,000	-12,902,000	-17,508,000	-17,688,000	-19,509,000
accounts receivable	-4,894,000	-1,580,000	1,273,000	-5,333,000	4,649,000	-7,688,000	-27,133,000
prepaid expenses and other assets	-2,234,000
accounts payable	1,463,000
accrued compensation and benefits	-21,009,000
accrued liabilities	-20,374,000
payments on royalty agreement	-3,721,000
operating lease liabilities	-212,000
net cash from operating activities	-62,906,000	-22,067,000	-13,576,000	-27,415,000	-47,979,000	-43,945,000	-58,942,000	-53,478,000	-62,253,000	-40,938,000	-50,839,000	-29,601,000	-46,365,000	-35,181,000	-29,582,000	-28,642,000	-33,974,000	-22,168,000	-22,840,000	-17,814,000	-32,734,000	-12,614,000	-15,449,000	-12,395,000	-26,194,000	-10,366,000	-11,980,000	-8,745,000	-12,738,000	-3,010,000	-6,136,000	-4,495,000	-7,368,000	-4,387,000																		-16,585,000	-21,367,000	-14,273,000	-14,044,000	-12,708,000	-16,155,000	-8,966,000	-9,806,000	-9,365,000	-11,602,000	-11,225,000	-11,257,000	-9,290,000	-11,349,000	-9,697,000	-3,428,000	-10,086,000	-5,869,000	-7,249,000	-5,377,000	-7,596,000	-3,915,000	-1,398,000	-7,556,000	-9,987,000	-4,931,000	-6,217,000	-7,561,000	-9,062,000	-6,234,000	-9,210,000
cash flows from investing activities:
purchases of property and equipment	-252,000	0	89,000	-170,000	32,000	141,000	0	-206,000	-615,000	-64,000	-192,000	-202,000	-372,000	-140,000	-171,000	-70,000	-50,000	-103,000	-94,000	0	-10,000	-11,000	-4,000	-195,000	-191,000	-89,000	-257,000	-22,000	-45,000	-7,000																						-84,000	-217,000	-135,000	-136,000	-124,000	-294,000	-122,000	-27,000	-393,000	-83,000	-108,000	-715,000	-529,000
purchases of marketable securities	-34,525,000	-104,219,000	-77,029,000	-76,696,000	-46,477,000	-184,791,000	-65,808,000	-160,715,000	-65,618,000	-15,867,000	-104,009,000	-114,107,000	-241,611,000	-160,671,000	-40,287,000	-38,945,000	-18,104,000	-60,952,000	-34,052,000	-57,308,000	-25,122,000	-93,135,000	-37,711,000	-175,442,000	-6,913,000	-51,191,000	-35,868,000	-22,316,000	-44,092,000	-38,645,000	-42,653,000	-87,299,000	-19,768,000	-18,746,000																		-17,895,000	-40,299,000	-33,826,000	-19,370,000	-51,395,000	-87,559,000	-37,029,000	-25,891,000	-32,935,000	-89,618,000	-31,124,000	-30,907,000	-48,460,000	-20,499,000	-21,965,000	-39,714,000	-19,483,000	-56,532,000	-39,147,000	-63,705,000	-15,511,000	-21,558,000	-34,776,000	-32,010,000	-12,232,000
proceeds from maturities and sales of marketable securities	86,633,000
net cash from investing activities	51,856,000	21,145,000	13,348,000	20,315,000	52,439,000	-103,511,000	-554,000	-36,146,000	34,207,000	47,569,000	-4,714,000	-44,444,000	-178,733,000	18,988,000	9,842,000	2,810,000	30,427,000	8,365,000	-5,406,000	30,905,000	38,083,000	-21,836,000	13,564,000	-129,206,000	32,158,000	-7,013,000	6,037,000	19,412,000	8,964,000	848,000	-9,349,000	-66,609,000	-2,608,000	9,744,000	7,722,000	-3,854,000	9,358,000										6,049,000	1,207,000	9,658,000	16,266,000	8,776,000	19,511,000	7,686,000	11,942,000	10,507,000	2,004,000	-66,251,000	6,104,000	11,023,000	672,000	-51,806,000	3,259,000	-13,345,000	-21,111,000	-1,290,000	4,423,000	-7,236,000	35,896,000	-14,419,000	1,799,000	-7,390,000		24,215,000			3,044,000	847,000	-10,830,000	10,182,000	-3,535,000	14,460,000	10,214,000
cash flows from financing activities:
proceeds from issuances of common stock from equity plans	914,000	878,000	542,000	591,000	256,000	5,987,000	3,574,000	16,373,000	6,749,000	3,580,000	1,044,000	573,000	7,875,000	223,000	1,201,000			593,000	0	187,000	17,000	111,000
proceeds from the exercise of warrants	1,511,000
net cash from financing activities	2,425,000	378,000	542,000	1,091,000	256,000	166,163,000	3,578,000	16,833,000	147,798,000	33,280,000	29,354,000	18,340,000	281,047,000	11,923,000	4,778,000			19,639,000	0	12,654,000	16,263,000	-581,000	23,976,000	144,265,000	686,000	10,272,000	8,984,000			8,000	9,087,000	82,320,000	1,553,000	1,074,000	0			90,000					1,477,000	105,000	105,000	97,620,000	433,000	49,000	11,000	1,000			-4,189,000	4,287,000	144,000	144,000	93,888,000	37,000	198,000	9,992,000	140,000	4,464,000	372,000	46,654,000	180,000	1,000	3,922,000	14,000	1,509,000	15,290,000	44,093,000	109,000	77,394,000	3,996,000	13,019,000	649,000	1,170,000	20,914,000	-136,000	-220,000	410,000	-168,000
net effect of exchange rates on cash, cash equivalents and restricted cash	-36,000
net increase in cash, cash equivalents and restricted cash	-8,661,000	-553,000	389,000	-6,006,000	4,734,000	18,678,000	-55,870,000	-72,812,000	119,742,000	39,893,000	-26,193,000	-55,704,000	55,933,000					5,836,000	-28,246,000	25,745,000	21,612,000	-35,031,000	22,091,000	2,664,000	6,650,000	-7,107,000	3,041,000					11,216,000	-8,423,000
cash, cash equivalents and restricted cash at the beginning of the period	79,440,000	0	0	0	80,876,000	0	0	0	71,138,000	0	0	0	57,209,000	0	0	0	35,235,000	0	0	0	10,288,000	0	0	0	13,914,000	0	0	0	10,844,000	0	0	0	16,603,000
cash, cash equivalents and restricted cash at the end of the period	70,779,000	-553,000	389,000	-6,006,000	85,610,000	18,678,000	-55,870,000	-72,812,000	190,880,000	39,893,000	-26,193,000	-55,704,000	113,142,000	-4,258,000	-14,954,000	44,732,000	31,689,000	5,836,000	-28,246,000	25,745,000	31,900,000	-35,031,000	22,091,000	2,664,000	20,564,000	-7,107,000	3,041,000	10,910,000	7,070,000	-2,154,000	-6,398,000	11,216,000	8,180,000
amortization of debt issuance costs/debt discount														224,000	399,000					194,000	180,000
loss of extinguishment of debt
stock-based compensation for services by non-employees		18,000	29,000	26,000	15,000	13,000	15,000	15,000	92,000	178,000	439,000	99,000	112,000	124,000	112,000	13,000	15,000	20,000	23,000	23,000	25,000	31,000	22,000	16,000	16,000	18,000	17,000	11,000	22,000	36,000	35,000	49,000	71,000	41,000	44,000	58,000	57,000	28,000	45,000	50,000	83,000	112,000	67,000	23,000	84,000	65,000	83,000
stock-based compensation for employees and directors		5,771,000	6,742,000	6,738,000	7,408,000	6,793,000	6,890,000	12,625,000	4,877,000	4,416,000	7,204,000	3,945,000	2,961,000	2,188,000	2,063,000	2,058,000	1,692,000	2,305,000	2,008,000	1,973,000	1,794,000	1,852,000	1,768,000	1,707,000	1,568,000	1,650,000	1,569,000	1,434,000	1,426,000	1,594,000	1,615,000	1,545,000	1,614,000	1,992,000	2,094,000	2,075,000	1,983,000	2,127,000	2,117,000	2,019,000	2,064,000	2,376,000	2,013,000	2,009,000	2,102,000	1,641,000	1,222,000	886,000	1,348,000	1,263,000	1,362,000	1,391,000	2,717,000	2,366,000	3,847,000	6,319,000	3,276,000	4,322,000	3,051,000	3,069,000	2,659,000	2,824,000	2,572,000	2,520,000
interest and other receivables
deposit and other assets
royalty financing obligation
proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs														0	0							0	-610,000
proceeds from exercise of warrants						976,000	4,000	365,000	49,000	0	28,310,000	17,767,000	59,835,000	11,525,000				0	0	2,467,000	12,000	0																																														0	163,000	15,000,000		0		0	12,500,000
proceeds from sale of future royalties
proceeds from debt financing, net of paid debt issuance costs and debt discounts																		14,895,000				-692,000
repayment of debt
prepaid expenses, interest receivable and other assets			1,340,000	515,000	-1,688,000		-533,000
current and noncurrent liabilities			21,370,000	-863,000	-20,621,000		9,560,000	4,810,000	-9,723,000		5,279,000	17,802,000	-11,997,000		27,982,000	-5,061,000	967,000		1,345,000	8,306,000	-2,515,000				-12,039,000
payment on royalty agreement			-3,798,000	-3,023,000	-3,682,000
proceeds from maturities of marketable securities			90,288,000	97,181,000	98,884,000	81,139,000	65,254,000	124,775,000	100,440,000	63,500,000	99,487,000	69,865,000	63,250,000	179,799,000	50,300,000	41,825,000	48,581,000	69,420,000	28,740,000	88,213,000	61,621,000	71,310,000	50,940,000	38,750,000	39,262,000	44,267,000	42,162,000	41,750,000	53,101,000	39,500,000	33,313,000	20,690,000	17,160,000	28,490,000	28,546,000	28,300,000	37,640,000	35,720,000	28,151,000	43,083,000			52,490,000	28,385,000	24,300,000	17,363,000	22,385,000	23,321,000	27,595,000	36,151,000	26,634,000	37,490,000	47,393,000	45,902,000	30,014,000	53,523,000	23,125,000	43,255,000	36,940,000	34,000,000	37,894,000	36,500,000	18,251,000	27,879,000	19,750,000	28,250,000	35,279,000	55,732,000	43,000,000	41,805,000	56,536,000	58,832,000	46,239,000	46,770,000	24,357,000	15,200,000
proceeds from issuance of common stock from offering and pre-funded warrant, net of paid issuance costs							0	-271,000	141,000,000
proceeds from employee stock purchase plan			0				0
effect of exchange rates on cash, cash equivalents and restricted cash			75,000	3,000	18,000		48,000	-21,000	-10,000		6,000	1,000	-16,000				1,000
current and noncurrent assets									-819,000		-16,105,000	496,000	1,915,000		-18,999,000	1,786,000	-7,293,000		-321,000	715,000	-3,757,000		-2,952,000	140,000	249,000		-1,013,000	1,146,000	-1,532,000
net gain on exchange and sales of equity investment																						0
prepaid and other current assets
proceeds from sales of equity investment																		0	0	0	1,594,000	0
proceeds from issuances of common stock from at market offerings, net of paid issuance costs																		4,151,000	0	0	16,234,000	0	0
proceeds from issuance of common stock from public offering and pre-funded warrant, net of paid issuance costs											0	0	213,337,000
debt discount and issuance costs for debt financing															-61,000
gain on sales of available for sale securities																						0
change in fair value of equity investment, including foreign currency translation																						24,000	92,000	-499,000	220,000	-16,000	209,000	106,000	-103,000	266,000	-175,000
amount due to janssen biotech, inc.																						0	0
proceeds from sales of securities available for sale																						0	0
gain on sales of equity investment																			0	0	-1,233,000
proceeds from debt financing
net effect of unrealized losses and exchange rates on cash, cash equivalents and restricted cash															8,000
net change in cash, cash equivalents and restricted cash															-14,954,000	44,733,000	-3,547,000
amortization related to 401(k) contributions																										0	0	0	9,000	-1,000	0	0	10,000	0	0	0	32,000	3,000	4,000	53,000	3,000	4,000	154,000	23,000	64,000	12,000	-16,000	362,000	103,000	55,000	109,000	172,000	79,000	178,000	217,000	235,000	133,000	162,000	159,000	193,000	78,000	117,000	172,000	127,000	58,000	116,000	89,000	57,000	76,000	41,000
gain on sale of marketable securities
proceeds from sale of marketable securities
proceeds from sales of marketable securities
amortization of right-of use-assets
other current and noncurrent liabilities																							4,883,000																												1,795,000	-1,783,000		1,024,000	217,000	154,000		731,000	94,000	208,000		695,000	1,525,000	1,292,000		100,000		-1,352,000	1,965,000	648,000		-116,000	4,623,000	645,000	-1,085,000	-1,768,000
gain on sale of available for sale securities
proceeds from issuance of common stock from equity plans
proceeds from issuances of common stock from financings																									686,000
loss on retirement/sales of property and equipment																																		0										0
prepaid assets
proceeds from issuances of common stock under equity plans
operating lease expense																											170,000
current liabilities																											2,564,000	2,928,000	-2,034,000		-438,000
proceeds from issuances of common stock, net of issuance costs																											8,984,000				9,087,000	82,320,000	1,553,000																	1,000												4,464,000	372,000	46,654,000		1,000		14,000	1,346,000	290,000		109,000	89,924,000	4,041,000	563,000		1,242,000
net decrease in cash, cash equivalents and restricted cash																													-3,774,000
proceeds from sales of property and equipment																																															1,000,000
loss on retirement of property and equipment																																				0	5,000
current assets																															-1,180,000
change in fair value of equity investment																																	125,000
other current and noncurrent assets																																	89,000														-344,000	903,000	345,000	77,000	480,000	1,384,000		312,000	1,088,000	2,157,000		1,575,000	904,000	1,299,000		-234,000	1,685,000	2,076,000		2,975,000		1,147,000	-47,000	455,000		1,345,000	1,295,000	330,000	204,000	-2,942,000
other current liabilities																																	-2,131,000		-5,304,000	-322,000	3,727,000	208,000	453,000	24,000
net income																																																					-31,854,000	-19,522,000	-21,088,000	-24,389,000	-59,362,000	-18,344,000	-17,031,000	-16,640,000	-18,391,000	-15,224,000	-19,758,000	-16,811,000	-17,632,000	-17,151,000	-11,045,000	-12,834,000	-13,985,000	1,167,000	-3,261,000	-9,837,000	-11,862,000	-3,082,000	-9,688,000	-51,683,000		-9,288,000	-7,932,000	-7,196,000	-9,008,000	-10,475,000
adjustments to reconcile net income to net cash from operating activities:
loss on sales of marketable securities
unrealized gain on derivatives																																																												-58,000		-966,000				162,000		247,000	36,000	-14,805,000
accrued collaboration charges
deferred revenue
restricted cash transfer																																																					0	0			0	0			0	0	26,000	-1,000	16,000	250,000							0
proceeds from sales/calls of marketable securities
proceeds from issuances of common stock																																		1,074,000	0
net increase in cash and cash equivalents																																					2,051,000															2,926,000			-3,393,000	-10,560,000			1,415,000	1,299,000				16,253,000	-12,459,000		-6,742,000			9,840,000	31,326,000					-6,294,000	-2,914,000	3,867,000	2,485,000	-12,817,000	8,636,000	836,000
cash and cash equivalents at the beginning of the period																																		0	0	0	12,810,000	0	0	21,248,000	0	0	42,796,000	0	0	12,990,000	0	0	22,063,000	0	0	16,105,000		0	0	45,972,000		0	0	34,601,000		0	0	109,348,000		0		0	0	135,882,000		0	0	0	9,846,000	12,823,000	0	0	4,604,000	0	0	18,773,000
cash and cash equivalents at the end of the period																																		6,431,000	3,298,000	-8,255,000	14,861,000	-2,316,000	-4,603,000	12,802,000	1,025,000	5,616,000	10,182,000	-1,920,000	-1,804,000	11,324,000	757,000	-6,671,000	15,505,000	1,885,000	-4,908,000	19,031,000		1,956,000	-3,393,000	35,412,000		-2,825,000	1,415,000	35,900,000		-3,502,000	-24,230,000	125,601,000		-5,273,000		25,824,000	-18,779,000	145,722,000		35,681,000	97,694,000	14,079,000	7,530,000	6,529,000	-2,914,000	3,867,000	7,089,000	-12,817,000	8,636,000	19,609,000
other current assets																																							206,000	813,000
net decrease in cash and cash equivalents																																																														-3,502,000													-2,316,000
supplemental disclosure of non-cash investing activities:
net unrealized gain on marketable securities																																					-18,000	-65,000	50,000	253,000
gain on sales of property and equipment
proceeds from issuance of common stock, net of issuance costs																																						90,000	241,000	826,000	210,000	78,000	1,477,000	105,000	105,000	97,620,000	433,000	49,000	11,000
net cash provided by financing activities																																								826,000
recognition of deferred revenue
proceeds from sales and maturities of marketable securities																																									49,752,000
loss on write-downs of property and equipment																																															0
unrealized loss on derivatives
translation adjustment																																																		153,000	0	16,000	-5,000	-8,000	0	12,000	-8,000	15,000	0	-3,000					-4,000		1,000				2,000	5,000	0	-10,000	-27,000	2,000
gain on sale of property and equipment
issuance of common stock in exchange for services by non-employees																																																	24,000	42,000	30,000	80,000		111,000	126,000	270,000		840,000	1,328,000	865,000		839,000	643,000	745,000
proceeds from sale of property and equipment																																																	104,000	18,000							0	0
accretion of discount on long-term debt																																																					18,000
interest expense on long-term debt
issuance of common stock for acquired in-process research and development																																																						0	0	594,000
loss on equity method investment
proceeds from sale of investments in licensees
proceeds from issuance of long-term debt																																																					2,140,000
issuance of common stock for acquired in-process research and
development
unrealized gain on fair value of derivatives																																																				-26,000	-73,000	-291,000	-240,000	-39,000								-77,000
proceeds from issuances of common stock and warrants, net of issuance costs																																																						5,000	144,000	144,000		37,000	198,000	9,992,000
cash flows from operating activities
loss on debt extinguishment
loss on retirement/sale of property and equipment																																																										0
loss on impairment of excess equipment
loss on sale of marketable securities
issuance of common stock in connection with acquired
in-process research technology
issuance of common stock and warrants in exchange for
services by non-employees
loss on investments in licensees																																																					0	0	168,000	335,000	1,212,000	243,000	496,000	396,000	682,000	6,000	20,000	656,000
deposits and other assets
accrued restructuring charges
advance payment from related party for research
and development																																																														-127,000	-72,000	-241,000
cash flows from investing activities
loan to related party																																																																	0
investment in licensee																																																													0
proceeds from sale of investment in licensees
cash flows from financing activities
repayment of long-term debt
distribution to ta therapeutics, ltd. shareholder
proceeds from issuance of common stock and warrants, net of issuance costs
cash and cash equivalents, at beginning of year
cash and cash equivalents, at end of year
supplemental disclosure of cash flow information
cash paid for interest
gain on retirement/sale of property and equipment																																																													3,000	126,000	0	1,000
stock issuance obligation for acquired in-process research and
issuance of common stock and warrants in exchange for services																																																																									1,478,000	305,000	2,725,000
by non-employees
accrued compensation
advance payment from related party for research and development																																																																	-298,000	-300,000	-409,000	-398,000
repurchase of common stock																																																																	0	0
unrealized (gain) loss on derivatives																																																										97,000
investments in licensees
proceeds from sale of fixed assets																																																																	0	0
gain on sale of fixed assets																																																																	3,000	0
amortization of intangible assets, principally research related																																																																							0	0	189,000	188,000	189,000	716,000
research funding payments
capital expenditures	-252,000	0	89,000	-170,000	32,000	141,000	0	-206,000	-615,000	-64,000	-192,000	-202,000	-372,000	-140,000	-171,000	-70,000	-50,000	-103,000	-94,000	0	-10,000	-11,000	-4,000	-195,000	-191,000	-89,000	-257,000	-22,000	-45,000	-7,000	0	0	0	0																		-84,000	-217,000	-135,000	-136,000	-124,000	-294,000	-122,000	-27,000	-393,000	-83,000	-108,000	-715,000	-529,000	-557,000	-612,000	-891,000	-353,000	-887,000	-859,000	-202,000	-156,000	-469,000	-345,000	-126,000	-125,000	-100,000	-111,000	-46,000	-51,000	-15,000	-259,000
free cash flows	-63,158,000	-22,067,000	-13,487,000	-27,585,000	-47,947,000	-43,804,000	-58,942,000	-53,684,000	-62,868,000	-41,002,000	-51,031,000	-29,803,000	-46,737,000	-35,321,000	-29,753,000	-28,712,000	-34,024,000	-22,271,000	-22,934,000	-17,814,000	-32,744,000	-12,625,000	-15,453,000	-12,590,000	-26,385,000	-10,455,000	-12,237,000	-8,767,000	-12,783,000	-3,017,000	-6,136,000	-4,495,000	-7,368,000	-4,387,000																		-16,669,000	-21,584,000	-14,408,000	-14,180,000	-12,832,000	-16,449,000	-9,088,000	-9,833,000	-9,758,000	-11,685,000	-11,333,000	-11,972,000	-9,819,000	-11,906,000	-10,309,000	-4,319,000	-10,439,000	-6,756,000	-8,108,000	-5,579,000	-7,752,000	-4,384,000	-1,743,000	-7,682,000	-10,112,000	-5,031,000	-6,328,000	-7,607,000	-9,113,000	-6,249,000	-9,469,000
payments of obligations under capital leases and equipment loans
stock-based compensation in exchange for services by non-employees																																																																		826,000		586,000	1,512,000	2,735,000
stock-based compensation for awards to employees and directors																																																																		3,092,000		2,934,000	2,569,000	2,922,000
loss recognized under equity method investments
loss on equity investments in licensees																																																																			43,000	0	35,000	28,000
stock-based compensation for stock grants to employees																																																																							0	0
accretion of interest on research funding obligation																																																																									0	122,000	123,000	123,000
unrealized (gain) loss on fair value of derivatives
notes receivable from related parties
equity investments in licensees
proceeds from sales of marketable equity investments in licensees
accrued research funding obligation																																																																								0	-222,000	-724,000	-871,000
payments of obligations under equipment loans																																																																								0	-30,000	-45,000	-44,000	-51,000	-72,000	-102,000	-137,000	-224,000	-215,000	-222,000
issuance of common stock in exchange for acquired in-process
research technology
unrealized (gain) loss on fair value of warrants to purchase
common stock
issuance of common stock and warrants in exchange for services by non-employees																																																																								117,000
stock-based compensation for options to employees and directors																																																																								996,000
amortization of deferred compensation																																																																								40,000	33,000	27,000	53,000	34,000
realized gain on equity investments in licensees																																																																								-1,000		-52,000	-3,000	-18,000
proceeds from sales of equity investments in licensees																																																																									0
gain on sale of fixed asset
proceeds from sale of fixed asset
net cash (used in)/provided by investing activities																																																																											-7,779,000
net (decrease)/increase in cash and cash equivalents
(gain) / loss on sale of fixed asset
issuance of common stock in exchange for acquired research technology
realized (gain)/loss on equity investments in licensees
net increase/(decrease) in cash and cash equivalents																																																																									97,694,000
loss on sale of fixed asset
proceeds from sale of equity investment in licensee																																																																												201,000
adjustments to reconcile net income to net cash from operating
activities:
interest for convertible debentures
conversion expense related to modification of series d
convertible debentures and warrants
issuance of common stock in exchange for acquired research
technology
stock-based compensation
realized loss on equity investments in licensees
issuance of common stock in exchange for acquired in-process research technology																																																																												45,150,000
issuance of common stock in exchange for services																																																																												100,000
accrued research funding payments																																																																												-896,000					-689,000	-527,000
proceeds from issuance of common stock																																																																												700,000			1,000	4,000	127,000	54,000
proceeds from equipment loans																																																																																0
purchases of securities available-for-sale																																																																																-17,200,000
proceeds from sales/calls of securities available-for-sale
proceeds from maturities of securities available-for-sale																																																																																12,500,000	19,276,000	11,000,000

Geron Corporation(NASDAQ:GERN)

Geron Corporation
(NASDAQ:GERN)